Efficacy of Different Statins Among Newly Diagnosed Dyslipidemic Patients in Dhulikhel Hospital

Background and Aims: Cardiovascular Disease is the leading cause of death. Prevention of cardiovascular disease is the major aim of treatment of anyone who has risk. Dyslipidemia lies in the center of cardiovascular disease risk. Not only there is difference in pattern of dyslipidemia and response t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nepalese heart journal 2023-06, Vol.20 (1), p.39-42
Hauptverfasser: Humagain, Sanjaya, Pathak, Surya Raj, Koju, Rajendra Prasad
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 42
container_issue 1
container_start_page 39
container_title Nepalese heart journal
container_volume 20
creator Humagain, Sanjaya
Pathak, Surya Raj
Koju, Rajendra Prasad
description Background and Aims: Cardiovascular Disease is the leading cause of death. Prevention of cardiovascular disease is the major aim of treatment of anyone who has risk. Dyslipidemia lies in the center of cardiovascular disease risk. Not only there is difference in pattern of dyslipidemia and response to statins in different ethnic groups, there is difference in mortality due to cardiovascular disease in different race and ethnic group. Atorvastatin and Rosuvastatin are the first line statins. This study is carried out to see how our population responds to these statins in terms of change in lipid profile. Methods: It is a real world observational study. Dyslipidemia patients requiring statins were given either Atorvastatin 10 mg or Rosuvastatin 5 mg according to physician’s discretion. Demographic profile and baseline lipid was recorded.  Lipid profile was again recorded after 3 to 4 months of treatment. Result: Out of 343 enrolled only 304 data was analyzed. Total cholesterol decreased by 21.9 % (p = 0.002) in Atorvastatin group and by 22.9 % (p= 0.002) in Rosuvastatin group. Low Density Lipoprotein (LDL) decreased by 22.3 % (p = 0.004) in Atorvastatin group and 21.5% (p=0.005) in Rosuvastatin group. There was no significant difference between two groups. Conclusion: Both Atorvastatin 10 mg and Rosuvastatin 5 mg can reduce the lipids significantly in our population. There is no difference in using Atorvastatin 10 mg or Rosuvastatin 5 mg. However, reduction was only mild to moderate with the given doses.
doi_str_mv 10.3126/njh.v20i1.55004
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_3126_njh_v20i1_55004</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3126_njh_v20i1_55004</sourcerecordid><originalsourceid>FETCH-LOGICAL-c125t-8378eff317132779b64fc9b5631979f3eddbb627b5bd95d1fc155c48cc0a4c4c3</originalsourceid><addsrcrecordid>eNpNkDlPwzAAhS0EElXpzOo_kNRHHNtj1RSKVAESMFuOj8Yll-IAyr8nFAam96R3DB8AtxilFJN83Z6q9JOggFPGEMouwIIgiRMiubj856_BKsYTQggTwbigC6B23gejzQQ7D4vgvRtcO8KXUY-hjXDTdO0RPrqveppTfWy76CwspliHPljXBAOf5-Y8iTC0sKg-6vBeuRruu9iHUdc34MrrOrrVny7B293udbtPDk_3D9vNITGYsDERlAvnPcUcU8K5LPPMG1mynGLJpafO2rLMCS9ZaSWz2BvMmMmEMUhnJjN0Cda_v2boYhycV_0QGj1MCiP1g0jNiNQZkTojot_481vs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy of Different Statins Among Newly Diagnosed Dyslipidemic Patients in Dhulikhel Hospital</title><source>Nepal Journals Online</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Humagain, Sanjaya ; Pathak, Surya Raj ; Koju, Rajendra Prasad</creator><creatorcontrib>Humagain, Sanjaya ; Pathak, Surya Raj ; Koju, Rajendra Prasad</creatorcontrib><description>Background and Aims: Cardiovascular Disease is the leading cause of death. Prevention of cardiovascular disease is the major aim of treatment of anyone who has risk. Dyslipidemia lies in the center of cardiovascular disease risk. Not only there is difference in pattern of dyslipidemia and response to statins in different ethnic groups, there is difference in mortality due to cardiovascular disease in different race and ethnic group. Atorvastatin and Rosuvastatin are the first line statins. This study is carried out to see how our population responds to these statins in terms of change in lipid profile. Methods: It is a real world observational study. Dyslipidemia patients requiring statins were given either Atorvastatin 10 mg or Rosuvastatin 5 mg according to physician’s discretion. Demographic profile and baseline lipid was recorded.  Lipid profile was again recorded after 3 to 4 months of treatment. Result: Out of 343 enrolled only 304 data was analyzed. Total cholesterol decreased by 21.9 % (p = 0.002) in Atorvastatin group and by 22.9 % (p= 0.002) in Rosuvastatin group. Low Density Lipoprotein (LDL) decreased by 22.3 % (p = 0.004) in Atorvastatin group and 21.5% (p=0.005) in Rosuvastatin group. There was no significant difference between two groups. Conclusion: Both Atorvastatin 10 mg and Rosuvastatin 5 mg can reduce the lipids significantly in our population. There is no difference in using Atorvastatin 10 mg or Rosuvastatin 5 mg. However, reduction was only mild to moderate with the given doses.</description><identifier>ISSN: 2091-2978</identifier><identifier>EISSN: 2091-2978</identifier><identifier>DOI: 10.3126/njh.v20i1.55004</identifier><language>eng</language><ispartof>Nepalese heart journal, 2023-06, Vol.20 (1), p.39-42</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0009-0002-8156-3675</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4122,27924,27925</link.rule.ids></links><search><creatorcontrib>Humagain, Sanjaya</creatorcontrib><creatorcontrib>Pathak, Surya Raj</creatorcontrib><creatorcontrib>Koju, Rajendra Prasad</creatorcontrib><title>Efficacy of Different Statins Among Newly Diagnosed Dyslipidemic Patients in Dhulikhel Hospital</title><title>Nepalese heart journal</title><description>Background and Aims: Cardiovascular Disease is the leading cause of death. Prevention of cardiovascular disease is the major aim of treatment of anyone who has risk. Dyslipidemia lies in the center of cardiovascular disease risk. Not only there is difference in pattern of dyslipidemia and response to statins in different ethnic groups, there is difference in mortality due to cardiovascular disease in different race and ethnic group. Atorvastatin and Rosuvastatin are the first line statins. This study is carried out to see how our population responds to these statins in terms of change in lipid profile. Methods: It is a real world observational study. Dyslipidemia patients requiring statins were given either Atorvastatin 10 mg or Rosuvastatin 5 mg according to physician’s discretion. Demographic profile and baseline lipid was recorded.  Lipid profile was again recorded after 3 to 4 months of treatment. Result: Out of 343 enrolled only 304 data was analyzed. Total cholesterol decreased by 21.9 % (p = 0.002) in Atorvastatin group and by 22.9 % (p= 0.002) in Rosuvastatin group. Low Density Lipoprotein (LDL) decreased by 22.3 % (p = 0.004) in Atorvastatin group and 21.5% (p=0.005) in Rosuvastatin group. There was no significant difference between two groups. Conclusion: Both Atorvastatin 10 mg and Rosuvastatin 5 mg can reduce the lipids significantly in our population. There is no difference in using Atorvastatin 10 mg or Rosuvastatin 5 mg. However, reduction was only mild to moderate with the given doses.</description><issn>2091-2978</issn><issn>2091-2978</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpNkDlPwzAAhS0EElXpzOo_kNRHHNtj1RSKVAESMFuOj8Yll-IAyr8nFAam96R3DB8AtxilFJN83Z6q9JOggFPGEMouwIIgiRMiubj856_BKsYTQggTwbigC6B23gejzQQ7D4vgvRtcO8KXUY-hjXDTdO0RPrqveppTfWy76CwspliHPljXBAOf5-Y8iTC0sKg-6vBeuRruu9iHUdc34MrrOrrVny7B293udbtPDk_3D9vNITGYsDERlAvnPcUcU8K5LPPMG1mynGLJpafO2rLMCS9ZaSWz2BvMmMmEMUhnJjN0Cda_v2boYhycV_0QGj1MCiP1g0jNiNQZkTojot_481vs</recordid><startdate>20230610</startdate><enddate>20230610</enddate><creator>Humagain, Sanjaya</creator><creator>Pathak, Surya Raj</creator><creator>Koju, Rajendra Prasad</creator><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0009-0002-8156-3675</orcidid></search><sort><creationdate>20230610</creationdate><title>Efficacy of Different Statins Among Newly Diagnosed Dyslipidemic Patients in Dhulikhel Hospital</title><author>Humagain, Sanjaya ; Pathak, Surya Raj ; Koju, Rajendra Prasad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c125t-8378eff317132779b64fc9b5631979f3eddbb627b5bd95d1fc155c48cc0a4c4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Humagain, Sanjaya</creatorcontrib><creatorcontrib>Pathak, Surya Raj</creatorcontrib><creatorcontrib>Koju, Rajendra Prasad</creatorcontrib><collection>CrossRef</collection><jtitle>Nepalese heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Humagain, Sanjaya</au><au>Pathak, Surya Raj</au><au>Koju, Rajendra Prasad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of Different Statins Among Newly Diagnosed Dyslipidemic Patients in Dhulikhel Hospital</atitle><jtitle>Nepalese heart journal</jtitle><date>2023-06-10</date><risdate>2023</risdate><volume>20</volume><issue>1</issue><spage>39</spage><epage>42</epage><pages>39-42</pages><issn>2091-2978</issn><eissn>2091-2978</eissn><abstract>Background and Aims: Cardiovascular Disease is the leading cause of death. Prevention of cardiovascular disease is the major aim of treatment of anyone who has risk. Dyslipidemia lies in the center of cardiovascular disease risk. Not only there is difference in pattern of dyslipidemia and response to statins in different ethnic groups, there is difference in mortality due to cardiovascular disease in different race and ethnic group. Atorvastatin and Rosuvastatin are the first line statins. This study is carried out to see how our population responds to these statins in terms of change in lipid profile. Methods: It is a real world observational study. Dyslipidemia patients requiring statins were given either Atorvastatin 10 mg or Rosuvastatin 5 mg according to physician’s discretion. Demographic profile and baseline lipid was recorded.  Lipid profile was again recorded after 3 to 4 months of treatment. Result: Out of 343 enrolled only 304 data was analyzed. Total cholesterol decreased by 21.9 % (p = 0.002) in Atorvastatin group and by 22.9 % (p= 0.002) in Rosuvastatin group. Low Density Lipoprotein (LDL) decreased by 22.3 % (p = 0.004) in Atorvastatin group and 21.5% (p=0.005) in Rosuvastatin group. There was no significant difference between two groups. Conclusion: Both Atorvastatin 10 mg and Rosuvastatin 5 mg can reduce the lipids significantly in our population. There is no difference in using Atorvastatin 10 mg or Rosuvastatin 5 mg. However, reduction was only mild to moderate with the given doses.</abstract><doi>10.3126/njh.v20i1.55004</doi><tpages>4</tpages><orcidid>https://orcid.org/0009-0002-8156-3675</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2091-2978
ispartof Nepalese heart journal, 2023-06, Vol.20 (1), p.39-42
issn 2091-2978
2091-2978
language eng
recordid cdi_crossref_primary_10_3126_njh_v20i1_55004
source Nepal Journals Online; EZB-FREE-00999 freely available EZB journals
title Efficacy of Different Statins Among Newly Diagnosed Dyslipidemic Patients in Dhulikhel Hospital
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A12%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20Different%20Statins%20Among%20Newly%20Diagnosed%20Dyslipidemic%20Patients%20in%20Dhulikhel%20Hospital&rft.jtitle=Nepalese%20heart%20journal&rft.au=Humagain,%20Sanjaya&rft.date=2023-06-10&rft.volume=20&rft.issue=1&rft.spage=39&rft.epage=42&rft.pages=39-42&rft.issn=2091-2978&rft.eissn=2091-2978&rft_id=info:doi/10.3126/njh.v20i1.55004&rft_dat=%3Ccrossref%3E10_3126_njh_v20i1_55004%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true